PharmacyCodes



Difenoxilato [Spanish] en es it fr

Difenoxilato [Spanish] Brand names, Difenoxilato [Spanish] Analogs

Difenoxilato [Spanish] Brand Names Mixture

  • Lomotil (Atropine Sulfate + Diphenoxylate Hcl)

Difenoxilato [Spanish] Chemical_Formula

C30H32N2O2

Difenoxilato [Spanish] RX_link

http://www.rxlist.com/cgi/generic3/diphenoxylate.htm

Difenoxilato [Spanish] fda sheet

Difenoxilato [Spanish] msds (material safety sheet)

Difenoxilato_[Spanish] MSDS

Difenoxilato [Spanish] Synthesis Reference

Janssen, U.S. pat. 2,898,340 (1959)

Difenoxilato [Spanish] Molecular Weight

452.587 g/mol

Difenoxilato [Spanish] Melting Point

221 oC

Difenoxilato [Spanish] H2O Solubility

0.8 mg/ml

Difenoxilato [Spanish] State

Solid

Difenoxilato [Spanish] LogP

7.385

Difenoxilato [Spanish] Dosage Forms

Oral solution; Tablet

Difenoxilato [Spanish] Indication

For as adjunctive therapy in the management of diarrhea

Difenoxilato [Spanish] Pharmacology

Diphenoxylate, an antidiarrheal, is effective as adjunctive therapy in the management of diarrhea. Diphenoxylate is rapidly and extensively metabolized in man by ester hydrolysis to diphenoxylic acid (difenoxine), which is biologically active and the major metabolite in the blood.

Difenoxilato [Spanish] Absorption

90%

Difenoxilato [Spanish] side effects and Toxicity

Coma, dry skin and mucous membranes, enlarged pupils of the eyes, extremely high body temperature, flushing, involuntary eyeball movement, lower than normal muscle tone, pinpoint pupils, rapid heartbeat, restlessness, sluggishness, suppressed breathing

Difenoxilato [Spanish] Patient Information

INFORM THE PATIENT (PARENT OR GUARDIAN) NOT TO EXCEED THE RECOMMENDED DOSAGE AND TO KEEP DIPHEN-OXYLATE HCL AND ATROPINE SULFATE OUT OF THE REACH OF CHILDREN AND IN A CHILD-RESISTANT CONTAINER, INFORM THE PATIENT OF THE CONSEQUENCES OF OVERDOSAGE, INCLUDING SEVERE RESPIRATORY DEPRESSION AND COMA, POSSIBLY LEADING TO PERMANENT BRAIN DAMAGE OR DEATH.

Diphenoxylate HCl and atropine sulfate may produce drowsiness or dizziness. The patient should be cautioned regarding activities requiring mental alertness, such as driving or operati ng dangerous machinery. Potentiation of the action of alcohol, barbiturates and tranquilizers with concomitant use of diphenoxylate HCl and atropine sulfate should be explained to the patient. The physician should also provide the patient with other information in this labeling, as appropriate.

Difenoxilato [Spanish] Organisms Affected

Humans and other mammals